ADVM Articles, Adverum Biotechnologies Inc.
home / stock / advm / advm articles
-
Over the past twenty days of trading, Adverum Biotechnologies Inc. (NASDAQ: ADVM), from September 27, 2019 to October 24, 2019 there is a potential...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medic...
-
- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD) - New data highlight ADVM-022 reductions in mean annualized anti-VEGF injections range ...
-
- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years - New evaluation of the impact of baseline levels of neutralizing antibodies (NAbs) to AAV.7m8 on ADVM-022 efficacy, safety and anato...